A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)

PHASE3TerminatedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

August 9, 2018

Primary Completion Date

May 1, 2020

Study Completion Date

May 1, 2020

Conditions
Refractory Major Depressive Disorder
Interventions
DRUG

ALKS 5461

samidorphan + buprenorphine administered sublingually

Trial Locations (34)

3121

Alkermes Investigational Site, Richmond

3174

Alkermes Investigational Site, Noble Park

3199

Alkermes Investigational Site, Frankston

10549

Alkermes Investigational Site, Mount Kisco

11432

Alkermes Investigational Site, Jamaica

18104

Alkermes Investigational Site, Allentown

21208

Alkermes Investigational Site, Pikesville

30030

Alkermes Investigational Site, Decatur

30341

Alkermes Investigational Site, Atlanta

32256

Alkermes Investigational Site, Jacksonville

32801

Alkermes Investigational Site, Orlando

32905

Alkermes Investigational Site, Palm Bay

33024

Alkermes Investigational Site, Hollywood

33319

Alkermes Investigational Site, Lauderhill

38119

Alkermes Investigational Site, Memphis

44718

Alkermes Investigational Site, Canton

45215

Alkermes Investigational Site, Cincinnati

63368

Alkermes Investigational Site, O'Fallon

72211

Alkermes Investigational Site, Little Rock

73112

Alkermes Investigational Site, Oklahoma City

75115

Alkermes Investigational Site, DeSoto

75390

Alkermes Investigational Site, Dallas

85712

Alkermes Investigational Site, Tucson

90660

Alkermes Investigational Site, Pico Rivera

90720

Alkermes Investigational Site, Los Alamitos

91403

Alkermes Investigational Site, Sherman Oaks

92054

Alkermes Investigational Site, Oceanside

92374

Alkermes Investigational Site, Redlands

92591

Alkermes Investigational Site, Temecula

92705

Alkermes Investigational Site, Santa Ana

98007

Alkermes Investigational Site, Bellevue

05091

Alkermes Investigational Site, Woodstock

00918

Alkermes Investigational Site, San Juan

00926

Alkermes Investigational Site, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY

NCT03610048 - A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD) | Biotech Hunter | Biotech Hunter